3^rd International Conference on Biomarkers and Clinical Research July 03-04, 2023 London, UK

Track 1: Biomarkers

A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Biomarker also called molecular marker and signature molecule.

• Diagnostic biomarker
• Monitoring biomarker
• Pharmacodynamic/response biomarker
• Predictive biomarker
• Prognostic biomarker

Track 2: Molecular Biomarkers in Cancer

Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer, occurrence of cancer, or patient outcome. They may include somatic genetic variants, epigenetic signatures, transcriptional changes and proteomic signatures. These indicators are based on biomolecules, such as nucleic acids and proteins, that can be detected in samples obtained from tissues through tumor biopsy or, more easily and non-invasively, from blood, saliva.

• Biomolecules
• Detection technologies
• Clinical applications of biomarkers
• Diagnosis and prognosis of Cancer
• Cancer Medicine

Track 3: Cancer Biomarker Discovery

Cancer biomarker discovery and development falls into five conceptual phases: preclinical exploratory studies; clinical assay and validation; retrospective longitudinal studies; prospective screening; and randomized control trials

• The discovery of oncogenes and tumor-suppressor genes
• Bioinformatics tools
• Clinical tests for detecting cancer

Track 4: Clinical Biomarkers

With the increasing sophistication of diagnostic processes and expanding knowledge about association between biomolecules, genomics and acute disease, interest in biomarkers is at an all-time high. Although there are many research studies into validating and understanding the prognostic and diagnostic value of biomarkers, this thematic series covers recent advances in the clinical applications of biomarkers

• Development of therapeutics
• Evaluation of therapeutic intervention on disease progression
• Clinical practice or Clinical trials

Track 5: Cancer Biomarkers

Cancer biomarkers are biological molecules produced by the body or tumor in a person with cancer. Biomarker testing helps characterize alterations in the tumor. Biomarkers can be DNA, RNA, protein or metabolomics profiles that are specific to the tumor. Testing can include genomic testing to look at the DNA sequence, DNA or RNA tests to look for gene fusions, or tests to measure RNA or protein levels.

• Cellular biomarkers
• Metabolomic biomarkers
• DNA biomarkers
• Biomarkers of drug response
• Tumor Suppressors Biomarkers

Track 6: Prognostic and predictive biomarkers

While prognostic biomarkers hint at the likely outcome of a patient with a particular disease regardless of their treatment, predictive biomarkers provide information on whether that patient will respond to a certain agent. Some markers provide both of these functions. For instance, estrogen receptor positivity in breast cancer patients indicates a favorable prognosis (providing prognostic information); at the same time, it means that the patient will probably respond to endocrine therapy.

• Prognostic Biomarkers: Analysis of Mutations and Polymorphisms
• Prognostic Biomarkers: Analysis of Gene and MicroRNA
• Predictive Biomarkers: Analysis of Mutations and Polymorphisms
• Predictive Biomarkers: Analysis of Gene and MicroRNA

Track 7: Biomarkers: Validation and Verification

The biomarker validation study represents a key step for the translation of the bench findings into clinical practice for tailored prescription or to accelerate the development of new drugs and other medical products. Biomarker validation is a multifaceted procedure that requires collaboration of multiple clinical centers and carries a significant financial burden and for which robust quantitative assays have been developed will enter the validation phase.

• Biomarker validation
• Biomarker identification

Track 8: Biomarkers and Personalized Medicine

Biomarkers are of increasingly high importance in medicine, particularly in 'personalized medicine'. They are valuable for predicting prognosis and dose selection. Moreover, they may be helpful in detecting therapeutic and adverse responses and in patient stratification based on efficacy or safety prediction. Thus, biomarkers are essential tools for the selection of appropriate patients for treatment with certain drugs to and enable personalized medicine that is 'providing the right treatment to the right patient.

• Personalized Medicine
• Cancer Medicine

Track 9: Digital Biomarkers

Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantables, or digestibles. The data collected are typically used to explain, influence, and/or predict health-related outcomes.

• Digital Health Technologies
• Human Factors and Digital Health
• Digital therapeutics
• Implementation strategies or models to minimize device discrepancy

Track 10: Cancer Therapy and Treatments

Cancer can be treated by way of unique processes. The selection of therapy depends upon the location and grade of the tumor and the level of the sickness, as well as the general country of the affected person). Many experimental most cancers treatments also are under improvement. a few people with cancer will have handiest one treatment. But most of the people have a combination of treatments, consisting of surgical treatment with chemotherapy and/or radiation remedy. You could also have immunotherapy, focused remedy, or hormone remedy.

• Immunotherapy
• Radiation Therapy
• Chemotherapy
• Hormonal Therapy
• Stem Cell Therapy

Track 11: Biomarker Research

Biomarker research has been revolutionized by the development of high-throughput technologies and artificial intelligence methods, yielding a prolific biomarker discovery phase. Additional efforts are needed now to develop the analytical infrastructure necessary to generate, integrate and analyze multi-omics data effectively.

• Clinical trials
• Artificial intelligence
• Applications in biomarker discovery

Track 12: Cancer Diagnosis and Screening

Diagnostic testing of malignancy includes the checks achieved by way of a pathologist to verify the segment of disorder, length of the tumor, region infected via the tumor, and so forth unique obsessive and histopathological procedures are utilized in malignancy conclusion. A portion of the simple systems for most cancers determination are biopsy, MRI, X-Ray and so forth A portion of various strategies which can be normally applied in recent times to apprehend or distinguish the malignancies beginning from an organ are endoscopy for gastrointestinal tumors, mammography for bosom illnesses and so on one of the lately designed strategies for area of organ characterized malignant growths is atomic medicinal drug imaging.

• Mammography
• Colonoscopy
• Nuclear imaging

Overview on biomarkers market:

The global biomarkers market has increased demand in recent years due to the rapid growth of population, rapid growth in IT industry which leads to increasing efforts towards the drug discovery. The entry of new entrepuners is expected to further boost the growth of the market. The advancements and innovations of biomarkers in medical arena such as research and cancer treatment will propel the future growth of the global biomarkers market. Biomarkers are broadly used to detect diseases such as immunological disorders, neurological disorders, cancer, cardiovascular disorders, and others. In the arena of oncology, recently three biological markers have been added to conventional breast cancer risk models to identify women at a higher risk of breast cancer

Global Vocal Biomarkers Market:

Sound vibrations are used as part of therapeutic healing for various mental health conditions such as anxiety and depression. Recent research studies, however, have greatly widened its applications into diagnosis of various diseases. On successful completion of clinical trials, HIPAA compliant vocal biomarker system would serve as much more alternative methods to current diagnostic techniques such as MRI, X-Ray, and CT scan. Research is also ongoing for identifying vocal biomarkers in diagnosis of Parkinson’s disease, traumatic brain injury, cognitive impairment, and respiratory disorders, which would open up a highly profitable avenue for growth for players in this industry. Since last 22 years companies dealing with vocal biomarkers are on researching by sampling data to provide accurate results and it has collected over 2.5 million voice samples in over 40 different languages.

Global Biomarkers Market is expected to USD $147.59  billion by 2028, from USD 31.4 billion in 2021 growing at a CAGR of 14.2% during the forecast period of 2021 to 2028. The new market report contains data for historic years 2018 & 2028, the base year of calculation is 2016 and the forecast period is 2017 to 2028.

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico, Brazil)
• Western Europe (Germany, Italy, U.K, Spain, France, Rest of Western Europe)
• Eastern Europe (Russia)
• Asia Pacific (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC, S. Africa)

Summary (Overall Market of Biomarkers & Clinical Research with Statistics):

The global biomarkers market is expected to reach $147.59 Billion by 2028 from $24.10 Billion in 2021, at a CAGR of 14.2% between 2021 and 2028. Increasing healthcare expenditure & R&D spending and the increasing utility of biomarkers for diagnostics are expected to drive the market. Market growth will also be aided by the low cost of clinical trials in developing countries and new initiatives undertaken for biomarker research. On the other hand, the need for high capital investment, low benefit-cost ratio, poorly suited regulatory & reimbursement systems, and the high cost of tests and sample collection & storage are the major factors restraining the growth of this market.

The applications included in this report are diagnostics development, drug discovery & development, personalized medicine, disease risk assessment and other applications. The disease indication segments included in this report are cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases.

Major players in this market include QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Merck & Co, Inc. (U.S.), Bio-Rad Laboratories (U.S.), Enzo Biochem (U.S.), EKF Diagnostics Holdings plc (U.S.), Meso Scale Diagnostics, LLC (U.S.), Singulex, Inc. (U.S.), BioSims Technologies (France), Cisbio Bioassays (France), and Signosis, Inc. (U.S.).

2^nd International Conference on Biomarkers and Clinical Research was organized during August 22-23, 2022, Webinar. The conference was marked with the attendance of Editorial Board Members of supporting journals, Scientists, young and brilliant researchers, business delegates and talented student communities, who made this conference fruitful and productive.

This conference was based on the theme “Biomarkers role in Achieving Clinical Progress with Research Methods” which included the following scientific tracks: 

• Biomarkers
• Molecular Biomarkers in Cancer
• Cancer Biomarker Discovery
• Clinical Biomarkers
• Cancer Biomarkers
• Prognostic and Predictive Biomarkers
• Biomarkers: Validation and Verification
• Biomarkers and Personalized Medicine
• Digital Biomarkers
• Cancer Therapy and Treatments

Conference Series LLC Ltd has taken the privilege of felicitating Biomarkers Conference 2022 Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this conference.

The esteemed guests, keynote speakers and researchers shared their innovative research and vast experience through their informative presentations at the podium of Biomarkers Conference 2022.

So as continuation of Biomarkers Conference 2022, we would like to heartily invite you to our upcoming 3^rd International Conference on Biomarkers and Clinical Research during July 03-04, 2023 London, UK

We look forward to seeing your benign presence with active contribution and support to make this event successful once more.